Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, February 22, 2023
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
[ Wed, Feb 22nd 2023
] - WOPRAI
Tiago Fauth Reiterated (ABCL) at Buy and Held Target at $34 on, Feb 22nd, 2023
Tiago Fauth of Credit Suisse, Reiterated "AbCellera Biologics Inc." (ABCL) at Buy and Held Target at $34 on, Feb 22nd, 2023.
Tiago has made no other calls on ABCL in the last 4 months.
There are 3 other peers that have a rating on ABCL. Out of the 3 peers that are also analyzing ABCL, 0 agree with Tiago's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Tiago
- Puneet Souda of "SVB Leerink" Maintained at Buy with Decreased Target to $18 on, Friday, January 6th, 2023
- Andrea Tan of "Goldman Sachs" Initiated at Strong Buy and Held Target at $30 on, Thursday, December 15th, 2022
- Robyn Karnauskas of "Truist Securities" Initiated at Strong Buy and Held Target at $29 on, Wednesday, November 16th, 2022
